Study To Estimate The Time Course Of PF-04764793 In The Blood Following Dosing By Oral Inhalation From Dry Powder Inhalers
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- Drug: Treatment ADrug: Treatment B
- Registration Number
- NCT00977015
- Lead Sponsor
- Pfizer
- Brief Summary
The purpose of this study is to investigate the time course of PF-04764793 concentration in the blood following dosing by oral inhalation from dry powder inhalers.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 36
Inclusion Criteria
- Healthy male and/or female subjects between the ages of 21 and 55 years.
- Body Mass Index (BMI) of 17.5 to 30.5 kg/m^2; and a total body weight >50 kg (110 lbs).
Exclusion Criteria
- Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at time of dosing).
- A positive urine drug screen.
- History of regular alcohol consumption exceeding 14 drinks/week for females or 21 drinks/week for males.
- Pregnant or nursing females.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- CROSSOVER
- Arm && Interventions
Group Intervention Description Treatment A - PF-04764793 Treatment A PF-04764793 using inhaler A Treatment B - PF-04764793 Treatment B PF-04764793 using inhaler B
- Primary Outcome Measures
Name Time Method Plasma pharmacokinetic parameters: AUClast and Cmax 48
- Secondary Outcome Measures
Name Time Method Plasma pharmacokinetic parameters: AUC0-12, AUC0-24, AUCinf, Tmax and terminal half-life. 48
Trial Locations
- Locations (1)
Pfizer Investigational Site
🇸🇬Singapore, Singapore